Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data

• Hoofdauteurs: Quanfeng Zhao (Auteur), Pan Ma (Auteur), Peishu Fu (Auteur), Jiayu Wang (Auteur), Kejing Wang (Auteur), Lin Chen (Auteur), Yang Yang (Auteur)
• Formaat: Boek
• Gepubliceerd in: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Background and purpose: poly-ADP ribose polymerase (PARP) inhibitors show impressive efficacy in a range of tumors. However, concerns about rare and fatal adverse events, including myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) have arisen. The aim of this study was to excavate...